GLP-1 Medications Show Promise in Cancer Risk Reduction

GLP-1 medications, sold under various brand names, are primarily used for treating diabetes, obesity, and sleep apnea. Their potential effects on cancer are still in early research stages. Recent studies indicate that GLP-1 obesity treatments may also help reduce cancer risk. These studies suggest the drugs could reverse obesity-related carcinogenic risks and have anti-inflammatory effects that may suppress tumors.

The American Society of Clinical Oncology recently highlighted four studies from its Journal of Clinical Oncology, focusing on GLP-1 drugs’ potential in cancer prevention and control. A significant study analyzed medical and prescription records of over 10,000 patients with early-stage cancer. Researchers found that GLP-1s reduced cancer risk in six out of seven types of cancer, with statistically significant reductions in breast, liver, colorectal, and non-small cell lung cancers. Kidney and prostate cancer risks declined mildly, while pancreatic cancer rates showed minimal impact.

For non-small cell lung cancer, the progression to Stage IV disease occurred in 22.3% of patients not using GLP-1 drugs, compared to 10% among those taking them. Initially developed as diabetes treatments, GLP-1 drugs alter the hormonal composition of the brain and gut, reducing hunger and slowing digestion. Their effects on metabolic levers have proven beneficial against obesity, heart disease, and sleep apnea and hold potential for treating addiction and cancer.

Current studies show correlation but not causation. Dr. Julie Gralow of ASCO notes that these analyses are based on retrospective medical data, lacking details like patient comorbidities, exercise, or diet. However, the data aligns with existing knowledge about obesity’s role in cancer and the importance of healthy living in illness and recovery.

Breast Cancer Risk Reduction

Another study at the conference analyzed mammogram images and prescription data, finding that women aged 45 to 80 who used GLP-1 drugs were 30% less likely to develop breast cancer. Weight loss is known to reduce cancer risks, whether through diet or surgical methods. However, co-author Elizabeth McDonald from the University of Pennsylvania observed greater protective effects with GLP-1 drugs compared to other treatments or lifestyle changes.

McDonald suggests that GLP-1 drugs may trigger additional metabolic pathways by regulating hunger and digestion hormones, potentially reducing inflammation—a recognized cancer driver.

New Research Underway

New trials are exploring how GLP-1s might affect chronic inflammation or immunosuppression, both of which can contribute to cancer growth. Oncologist Coral Omene from Rutgers Cancer Institute plans a study with 40 breast cancer patients starting the GLP-1 drug tirezepatide, known as Mounjaro and Zepbound. Omene will monitor blood samples and track cancer markers, conducting biannual biopsies of abdominal fat cells to assess hormonal and inflammatory responses.

“As we treat them, we will trace and observe immune cell behavior,” Omene explains. This information aims to enhance understanding of GLP-1 drugs’ use against cancer.